Exercise Following Bariatric Surgery for Severe/Morbid Obesity (EFIBAR) (EFIBAR)

September 4, 2023 updated by: Enrique García Artero, Universidad de Almeria

Supervised Exercise Following Bariatric Surgery in the Treatment of Severe/Morbid Obesity: a Randomized Controlled Trial

Severe/morbid obesity is an international public health issue that importantly increases the risk of cardiovascular events and cardiovascular and all-cause mortality. Likewise, severe/morbid obesity increases the risk of illness, reduces quality of life, and raises health-care costs. Bariatric surgery is the election method for the treatment of severe/morbid obesity, resulting in significant weight loss and remission of comorbidities. However, a relatively large proportion of bariatric patients regain weight and continue to be at high risk for cardiovascular disease and premature mortality. A healthy lifestyle following bariatric surgery is essential for optimizing and maintaining weight loss. Observational studies suggest that physical activity following bariatric surgery might be associated with additional weight loss and more effective weigh loss maintenance over time. However, very little experimental evidence exists regarding the effects of supervised exercise on obesity-related outcomes in this specific population.

The aim of the EFIBAR (Ejercicio FÍsico tras cirugía BARiátrica) randomized controlled trial is to determine the effects of a 16-week supervised concurrent (aerobic and strength) exercise intervention program, on weight loss (primary outcome), body composition, cardiometabolic risk, physical fitness and quality of life (secondary outcomes) in patients with severe/morbid obesity following bariatric surgery.

According to the study aims the investigators pursue the following hypothesis: Supervised exercise will result in larger weight loss than control.

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Almería, Spain, 04009
        • Complejo Hospitalario Torrecárdenas (CHT)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • To comply with local bariatric surgery criteria:

    1. Patients with BMI ≥ 40 kg/m2 (or 35 kg/m2 with comorbidities).
    2. Acceptable surgical risk (defined by the approval of anesthetist).
    3. Obesity maintained for over 5 years.
    4. Failure of previous treatments.
    5. To sign informed consent for surgical treatment.
  • Not to present contraindications for supervised physical exercise.
  • To reside in the city of Almeria (Spain) or willingness/predisposition to attend the training sessions 3 times a week during 16 weeks

Exclusion Criteria:

  • Severe psychiatric or neurological disorders such as schizophrenia, epilepsia, Alzheimer, Parkinson, personality disorders, eating behaviour disorders, untreated depression or suicidal tendencies.
  • Adrenal or thyroid pathology that might cause obesity.
  • Uncontrolled addiction to alcohol or drugs.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Exercise
Usual care PLUS concurrent (aerobic and strength) supervised exercise program of 16 weeks (3 sessions/week, 60 min/session, progressively increasing in volume and intensity). The program will be conducted by certified Exercise Science professionals.
Concurrent (aerobic and strength) supervised exercise program: the program comprises 3 sessions/week (60 min/session) of aerobic and strength exercises of progressive volume and intensity. The program will follow the Consensus on Exercise Reporting Template (CERT) guidelines.
Other Names:
  • Exercise training
No Intervention: Control
Usual care routinely delivered after bariatric surgery, based on national (Spanish) and international recommendations, focused on nutritional status monitoring and diet/physical activity counseling.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percent total weight loss (%TWL) [Biospace Co., InBody 270, USA]
Time Frame: Changes from baseline to 4-month and 1-year follow-up
%TWL = [(pre-surgery weight - post-surgery weight) / (pre-surgery weight)] x 100
Changes from baseline to 4-month and 1-year follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body composition: body fat
Time Frame: Changes from baseline to 4-month and 1-year follow-up
Percent body fat (%) assessed by bioimpedance analysis (InBody 270, Biospace Co., USA)
Changes from baseline to 4-month and 1-year follow-up
Body composition: fat-free mass
Time Frame: Changes from baseline to 4-month and 1-year follow-up
Fat-free mass (kg) assessed by bioimpedance analysis (InBody 270, Biospace Co., USA)
Changes from baseline to 4-month and 1-year follow-up
Body composition: fat-free mass index
Time Frame: Changes from baseline to 4-month and 1-year follow-up
Fat-free mass index (kg/m2) assessed by bioimpedance analysis (InBody 270, Biospace Co., USA)
Changes from baseline to 4-month and 1-year follow-up
Body composition: central body fat
Time Frame: Changes from baseline to 4-month and 1-year follow-up
Waist and hip circumferences (measured in cm with an anthropometric tape), waist / height ratio
Changes from baseline to 4-month and 1-year follow-up
Lipid profile assessed from blood sample
Time Frame: Changes from baseline to 4-month and 1-year follow-up
Total cholesterol (mg/dl), HDL-cholesterol (mg/dl), LDL-cholesterol (mg/dl) and triglycerides (mg/dl)
Changes from baseline to 4-month and 1-year follow-up
Blood markers of glucose metabolism: glucose
Time Frame: Changes from baseline to 4-month and 1-year follow-up
Glucose (mg/dL)
Changes from baseline to 4-month and 1-year follow-up
Blood markers of glucose metabolism: insulin
Time Frame: Changes from baseline to 4-month and 1-year follow-up
Insulin (μUI/mL)
Changes from baseline to 4-month and 1-year follow-up
Blood markers of glucose metabolism: HOMA-IR
Time Frame: Changes from baseline to 4-month and 1-year follow-up
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
Changes from baseline to 4-month and 1-year follow-up
Blood markers of glucose metabolism: glycated hemoglobin HbA1c
Time Frame: Changes from baseline to 4-month and 1-year follow-up
Glycated hemoglobin HbA1c (%)
Changes from baseline to 4-month and 1-year follow-up
Brachial and central blood pressures (mmHg)
Time Frame: Changes from baseline to 4-month and 1-year follow-up
Systolic and diastolic blood pressures assessed by Mobil-O-Graph
Changes from baseline to 4-month and 1-year follow-up
Arterial stiffness
Time Frame: Changes from baseline to 4-month and 1-year follow-up
Pulse wave velocity (PWV, m/s) by Mobil-O-Graph
Changes from baseline to 4-month and 1-year follow-up
Plasma concentrations of inflammatory markers
Time Frame: Changes from baseline to 4-month and 1-year follow-up
High-sensitivity C-reactive protein (hs-CRP)
Changes from baseline to 4-month and 1-year follow-up
Plasma concentrations of inflammatory markers
Time Frame: Changes from baseline to 4-month and 1-year follow-up
Tumor necrosis factor (TNF-alpha)
Changes from baseline to 4-month and 1-year follow-up
Plasma concentrations of inflammatory markers
Time Frame: Changes from baseline to 4-month and 1-year follow-up
Interleukin 6 (IL-6)
Changes from baseline to 4-month and 1-year follow-up
Plasma concentrations of liver metabolism enzymes
Time Frame: Changes from baseline to 4-month and 1-year follow-up
GGT (gamma-glutamyltransferase)
Changes from baseline to 4-month and 1-year follow-up
Plasma concentrations of liver metabolism enzymes
Time Frame: Changes from baseline to 4-month and 1-year follow-up
GPT (glutamate-pyruvate transaminase)
Changes from baseline to 4-month and 1-year follow-up
Plasma concentrations of liver metabolism enzymes
Time Frame: Changes from baseline to 4-month and 1-year follow-up
GOT (glutamate-oxalacetate transaminase)
Changes from baseline to 4-month and 1-year follow-up
Plasma levels of Vitamin D
Time Frame: Changes from baseline to 4-month and 1-year follow-up
Concentrations of 25-hydroxyvitamin D (ng/mL)
Changes from baseline to 4-month and 1-year follow-up
Heart rate variability (HRV)
Time Frame: Changes from baseline to 4-month and 1-year follow-up
Assessed by heart rate monitor (Polar V800)
Changes from baseline to 4-month and 1-year follow-up
Health-related physical fitness: cardiorespiratory fitness
Time Frame: Changes from baseline to 4-month and and 1-year follow-up
Cardiorespiratory fitness, assessed using a maximal treadmill test
Changes from baseline to 4-month and and 1-year follow-up
Health-related physical fitness: upper body muscular strength
Time Frame: Changes from baseline to 4-month and and 1-year follow-up
Upper body muscular strength, assessed using handgrip dynamometry (kg)
Changes from baseline to 4-month and and 1-year follow-up
Health-related physical fitness: lower body muscular strength
Time Frame: Changes from baseline to 4-month and and 1-year follow-up
Lower body muscular strength, assessed using the 30-seconds chair-stand test (number of repetitions)
Changes from baseline to 4-month and and 1-year follow-up
Health-related physical fitness: upper body flexibility
Time Frame: Changes from baseline to 4-month and and 1-year follow-up
Upper body flexibility, assessed using the back scratch test (cm)
Changes from baseline to 4-month and and 1-year follow-up
Objectively-measured physical activity
Time Frame: Changes from baseline to 4-month and 1-year follow-up
Assessed by accelerometry (ActiGraph, software ActiLife)
Changes from baseline to 4-month and 1-year follow-up
Health-Related Quality of Life (HRQoL): SF-36
Time Frame: Changes from baseline to 4-month and 1-year follow-up
Measured by the 36-item Short Form Health Survey (SF-36)
Changes from baseline to 4-month and 1-year follow-up
Health-Related Quality of Life (HRQoL): EQ-5D-3L
Time Frame: Changes from baseline to 4-month and 1-year follow-up
Measured by European Quality of Life - 5 Dimensions-3Levels (EQ-5D-3L)
Changes from baseline to 4-month and 1-year follow-up
Symptomatology and function of hip / knee osteoarthritis: Pain
Time Frame: Changes from baseline to 4-month and 1-year follow-up
Measured by the WOMAC (Western Ontario and McMaster Universities) Osteoarthritis Index. The PAIN scale within the WOMAC questionnaire contains 5 items, each one scoring from 0 (Nothing) to 4 (Very much), what makes a total score ranging from 0 (better) to 20 (worse).
Changes from baseline to 4-month and 1-year follow-up
Symptomatology and function of hip / knee osteoarthritis: Function
Time Frame: Changes from baseline to 4-month and 1-year follow-up
Measured by the WOMAC (Western Ontario and McMaster Universities) Osteoarthritis Index. The FUNCTION scale within the WOMAC questionnaire contains 17 items, each one scoring from 0 (No trouble) to 4 (Very much difficult), what makes a total score ranging from 0 (better) to 68 (worse).
Changes from baseline to 4-month and 1-year follow-up
Symptomatology and function of hip / knee osteoarthritis: Stiffness
Time Frame: Changes from baseline to 4-month and 1-year follow-up
Measured by the WOMAC (Western Ontario and McMaster Universities) Osteoarthritis Index. The STIFFNESS scale within the WOMAC questionnaire contains 2 items, each one scoring from 0 (Nothing) to 4 (Very much), what makes a total score ranging from 0 (better) to 8 (worse).
Changes from baseline to 4-month and 1-year follow-up
Depression, anxiety and stress
Time Frame: Changes from baseline to 4-month and 1-year follow-up
Measured by the Depression, Anxiety and Stress Scale short form (DASS-21). The DASS-21 comprises three sub-scales assessing specific psychiatric symptoms (i.e., depression, anxiety, and stress). Each of these symptoms is assessed using seven items rated on a 4-point Likert-type scale (i.e., 0 = ''Did not apply to me at all''; 3 = ''Applied to me very much, or most of the time''). Summed score for each psychiatric symptom ranges from 0 to 21. Higher scores in each sub-scale indicate higher levels of depressive, anxiety or stress symptomatology. According to the specific nature of the three psychiatric symptoms assessed by the DASS-21, these are treated independently so that no total score is available.
Changes from baseline to 4-month and 1-year follow-up
Emotional, psychological and social well-being
Time Frame: Changes from baseline to 4-month and 1-year follow-up
Measured by the Mental Health Continuum-Short Form (MHC-SF)
Changes from baseline to 4-month and 1-year follow-up
Cost-effectiveness analysis (CEA)
Time Frame: From baseline to 1-year follow-up
The costs will consider those related to the surgery, the exercise program, prescription medication, sick leave, post-surgery complications and readmission rates, time and effort requiring each treatment, as well as possible dietary and informal care costs. Effectiveness will be considered as changes observed in the main clinical outcomes: weight loss and cardiometabolic risk (remission/relapse of hypertension, dyslipidemia and type 2 diabetes).
From baseline to 1-year follow-up
Cost-utility analysis (CUA)
Time Frame: From baseline to 1-year follow-up
The costs will consider those related to the surgery, the exercise program, prescription medication, sick leave, post-surgery complications and readmission rates, time and effort requiring each treatment, as well as possible dietary and informal care costs. Utility will evaluate variation in quality of life experienced by participants, computed as changes in quality-adjusted life years (QALY) using SF-36 questionnaire.
From baseline to 1-year follow-up
Cost-utility analysis (CUA)
Time Frame: From baseline to 1-year follow-up
The costs will consider those related to the surgery, the exercise program, prescription medication, sick leave, post-surgery complications and readmission rates, time and effort requiring each treatment, as well as possible dietary and informal care costs. Utility will evaluate variation in quality of life experienced by participants, computed as changes in quality-adjusted life years (QALY) using EQ-5D-3L questionnaire.
From baseline to 1-year follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Enrique G Artero, Ph.D., Universidad de Almeria

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2018

Primary Completion (Actual)

September 30, 2022

Study Completion (Actual)

September 30, 2022

Study Registration Dates

First Submitted

March 7, 2018

First Submitted That Met QC Criteria

April 10, 2018

First Posted (Actual)

April 13, 2018

Study Record Updates

Last Update Posted (Actual)

September 7, 2023

Last Update Submitted That Met QC Criteria

September 4, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All IPD will be shared once the study is finalised and the main results are published. IPD can be obtained by contacting the responsible party (artero@ual.es).

IPD Sharing Time Frame

Two years (24 months) after the study completion.

IPD Sharing Access Criteria

The PI must be contacted and a minimum number of co-authors from the research team must be included in any publication.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity, Morbid

Clinical Trials on Exercise

3
Subscribe